H01AC09 · Systemic hormonal preparations
Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
Indications
Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD])
Composition
- Active substance
- Lonapegsomatropin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
- Active substance
- Lonapegsomatropin
- ATC code
- H01AC09
- Therapeutic area
- Growth and Development
- Marketing authorisation holder
- Ascendis Pharma Endocrinology Division A/S
- Status
- Authorised